Immune Pharmaceuticals Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of novel targeted therapeutic agents in the fields of immunology, inflammation, dermatology and oncology. It operates though acquiring, developing and commercializing prescription drug products. Its lead product is bertilimumab, which is a fully human, anti-eotaxin-1, a regulator of immuno-inflammation. The Company is developing NanoCyclo, which is a nano-encapsulated formulation of cyclosporine-A for the treatment of atopic dermatitis and psoriasis. The CompanyÔÇÖs oncology portfolio includes Ceplene, which a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.
Number of employees : 7 people.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Heights Capital Management, Inc. ||251,029||
|Barclays Capital, Inc. ||187,059||
|Renaissance Technologies LLC ||138,205||
|The Vanguard Group, Inc. ||136,841||
|Edmond de Rothschild (Suisse) SA (Private Banking) ||86,325||
|Hudson Bay Capital Management LP ||64,159||
|Anson Funds Management LP ||41,935||
|Credit Suisse Securities (USA) LLC (Broker) ||38,399||
|Intellectus Partners LLC ||31,082||
|Goldman Sachs & Co. LLC (Private Banking) ||28,405||
|Company contact information|
Immune Pharmaceuticals, Inc.
1 Bridge Plaza North
Englewood Cliffs, NJ 07024
Phone : +1.201.464.2677
Web : http://www.immunepharma.com
Sector Other Pharmaceuticals
Connections : Immune Pharmaceuticals, Inc.